1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

01 Apr 2024
Admin
News Article

Alebund AP303 Granted FDA Orphan Drug Designation

Alebund AP303 Granted FDA Orphan Drug Designation for Autosomal Dominant Polycystic Kidney Disease

Overview

Alebund Pharmaceuticals, a biopharmaceutical company dedicated to pioneering therapies for renal diseases and related chronic ailments, announced today that the US Food and Drug Administration (FDA) has bestowed Orphan Drug Designation (ODD) upon AP303 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

Words from CEO: Alebund

Dr. Gavin Xia, Co-founder, Chairman, and CEO of Alebund, expressed enthusiasm, stating, ""The FDA's granting of Orphan Drug Designation to AP303 marks a significant milestone for Alebund and our commitment to addressing the substantial unmet medical needs associated with ADPKD. We eagerly anticipate advancing AP303 to enhance treatment options for patients in need.""

About AP303 and Epidemiology

AP303, an innovative drug candidate developed internally by Alebund, has shown promising results in improving renal survival in an ADPKD mouse model.
Following the completion of its first-in-human study in healthy subjects in Australia, AP303 is poised for a Phase II trial in ADPKD patients.
ADPKD affects between 1 in 400 and 1 in 1,000 live births and stands as a significant contributor to end-stage kidney disease (ESKD) necessitating renal replacement therapy.
The Orphan Drug Designation underscores the demand for novel treatment options and the potential of AP303 to address the urgent needs of individuals living with ADPKD.

ODD: Specialized Status for Development of Treatments

The US FDA's ODD is a specialized status granted to facilitate the development and assessment of potential new medications aimed at treating, diagnosing, or preventing rare diseases or disorders affecting fewer than 200,000 people in the US.
This designation offers incentives to advance the development of treatments for rare diseases, including marketing exclusivity, tax credits for clinical research expenses, and exemption from prescription drug user fees.

About ADPKD

ADPKD, the most prevalent monogenic kidney disease globally, is a leading cause of end-stage kidney disease in adults.
It is characterized by the formation and progressive enlargement of multiple cysts throughout the kidney tissue.
ADPKD primarily stems from mutations in the PKD1 gene (in 78% of cases) or the PKD2 gene (in 15% of cases).
Current treatment recommendations for ADPKD patients include antihypertensive therapy, dietary modifications, and pharmacotherapy for a limited subset of eligible patients.
However, there is a pressing need for more universally applicable treatment options with fewer side effects to effectively slow kidney function decline and enhance kidney outcomes in ADPKD patients.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!